STOCK TITAN
  1. Home
  2. News
  3. SPRB

Spruce Biosciences, Inc. - SPRB STOCK NEWS

Welcome to our dedicated page for Spruce Biosciences news (Ticker: SPRB), a resource for investors and traders seeking the latest updates and insights on Spruce Biosciences stock.

Spruce Biosciences, Inc. (SPRB) is a clinical-stage biopharmaceutical company pioneering non-steroidal therapies for rare endocrine disorders. This page serves as the definitive source for verified news and developments surrounding SPRB's innovative research and clinical programs.

Investors and medical professionals will find timely updates on clinical trial progress, regulatory milestones, and strategic partnerships. Our curated content includes updates on SPRB's lead candidate tildacerfont for congenital adrenal hyperplasia (CAH), financial disclosures, and scientific conference presentations.

Key information categories include:
- Clinical trial phase updates
- Regulatory agency communications
- Peer-reviewed research publications
- Strategic industry collaborations
- Financial performance summaries

Bookmark this page for direct access to SPRB's official announcements, maintaining informed perspectives on therapeutic advancements in endocrine care.

News

Spruce Biosciences Provides Clinical Program Updates and Outlook for 2024

Rhea-AI Summary
Spruce Biosciences, a late-stage biopharmaceutical company (Nasdaq: SPRB), is making significant progress in developing novel therapies for rare endocrine disorders, with upcoming milestones including topline results from CAHmelia-203 and CAHptain-205 in March 2024, and from CAHmelia-204 in Q3 2024. The company also anticipates maintaining cash runway into the first half of 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.49%
Tags
none
-
News

Spruce Biosciences Reports Third Quarter 2023 Financial Results and Provides Corporate Updates

Rhea-AI Summary
Spruce Biosciences, Inc. (Nasdaq: SPRB) reported financial results for Q3 2023, highlighted by the completion of enrollment in the CAHptain-205 and CAHmelia-203 studies for rare endocrine disorders. The company also provided updates on upcoming milestones and financial results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.7%
Tags
earnings
-
News

Spruce Biosciences to Participate in the Jefferies London Healthcare Conference

Rhea-AI Summary
Spruce Biosciences, Inc. (Nasdaq: SPRB) will participate in the Jefferies London Healthcare Conference on November 14-16, 2023. Archived webcasts from investor conferences are available on the company's investor relations website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.23%
Tags
conferences
News

Spruce Biosciences Completes Target Enrollment of CAHmelia-203 Study in Adult Classic Congenital Adrenal Hyperplasia

Rhea-AI Summary
Spruce Biosciences has announced the completion of target enrollment in the CAHmelia-203 clinical trial for the treatment of adult classic congenital adrenal hyperplasia (CAH). The company has enrolled 72 patients and closed screening in the trial. Final enrollment is expected to exceed the original target due to substantial patient interest. The topline results from this study, along with the results from all cohorts in the CAHptain clinical trial, are anticipated in the first quarter of 2024. Spruce Biosciences also provided updated anticipated milestones for other ongoing trials.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.97%
Tags
none
-
News

Spruce Biosciences to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

Rhea-AI Summary
Spruce Biosciences to present at H.C. Wainwright 25th Annual Global Investment Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
News

Spruce Biosciences Reports Second Quarter 2023 Financial Results and Provides Corporate Updates

Rhea-AI Summary
Spruce Biosciences, Inc. (Nasdaq: SPRB) reported interim data from the Phase 2 POWER Proof-of-Concept Study in Polycystic Ovary Syndrome (PCOS) and provided corporate updates. The study assessed the ability of tildacerfont to reduce DHEAS in women with PCOS. The interim results support target engagement and suggest that DHEAS may be reduced with tildacerfont treatment. Enrollment in the CAHmelia program in adult classic CAH surpassed 75%, and screening for Cohort 3 in the CAHptain Study for pediatric classic CAH is underway. The company also reported financial results for the second quarter ended June 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.37%
Tags
earnings
News

Spruce Biosciences Announces Acceptance of Abstract for Presentation at the Annual Meeting of the Endocrine Society (ENDO 2023)

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.35%
Tags
none
-
News

Spruce Biosciences Appoints Percival Barretto-Ko to Board of Directors

Rhea-AI Summary
Spruce Biosciences appoints Percival Barretto-Ko to its Board of Directors and announces the departure of Dina Chaya. Barretto-Ko brings over 20 years of commercial and biopharmaceutical expertise. The company is focused on developing novel therapies for rare endocrine disorders. Barretto-Ko's global experience will be valuable as Spruce prepares for the potential commercialization of tildacerfont.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.08%
Tags
management
-
News

Spruce Biosciences to Participate in the Jefferies Healthcare Conference

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.08%
Tags
conferences
News

Spruce Biosciences Honored at CARES Foundation 15th Annual Everyone CARES Gala

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.58%
Tags
none
Stock SPRB logo
Spruce Biosciences, Inc.

Nasdaq:SPRB

SPRB Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends
#1 Top Loser

SPRB Stock Data

5.01M
37.45M
11.57%
44.05%
1.03%
Biotechnology
Pharmaceutical Preparations
Link
United States
SOUTH SAN FRANCISCO